Gastroenterology
Volume 129, Issue 3 , Pages 1117-1120 , September 2005

Inflammatory Bowel Disease Extending Its Reach

  • Edward V. Loftus Jr

      Affiliations

    • Corresponding Author InformationAddress requests for reprints to: Edward V. Loftus, Jr, MD, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street, SW, Rochester, Minnesota 55905; fax: (507) 266-0335.

References 

  1. Bernstein CN , Wajda A , Blanchard JF . The clustering of other chronic inflammatory diseases in inflammatory bowel disease (a population-based study) . Gastroenterology . 2005;129:827–836
  2. Gupta G , Gelfand JM , Lewis JD . Increased risk of demyelinating diseases in patients with inflammatory bowel disease . Gastroenterology . 2005;129:819–826
  3. Bernstein CN , Blanchard JF , Rawsthorne P , Wajda A . Epidemiology of Crohn’s disease and ulcerative colitis in a central Canadian province (a population-based study) . Am J Epidemiol . 1999;149:916–924
  4. Bernstein CN , Blanchard JF , Rawsthorne P , Yu N . The prevalence of extraintestinal diseases in inflammatory bowel disease (a population-based study) . Am J Gastroenterol . 2001;96:1116–1122
  5. Bernstein CN , Blanchard JF , Kliewer E , Wajda A . Cancer risk in patients with inflammatory bowel disease (a population-based study) . Cancer . 2001;91:854–862
  6. Bernstein CN , Blanchard JF , Leslie W , Wajda A , Yu BN . The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study . Ann Intern Med . 2000;133:795–799
  7. Bernstein CN , Blanchard JF , Houston DS , Wajda A . The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease (a population-based cohort study) . Thromb Haemost . 2001;85:430–434
  8. Lewis JD , Brensinger C , Bilker WB , Strom BL . Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease . Pharmacoepidemiol Drug Safety . 2002;11:211–218
  9. Lewis JD , Bilker WB , Brensinger C , Deren JJ , Vaughn DJ , Strom BL . Inflammatory bowel disease is not associated with an increased risk of lymphoma . Gastroenterology . 2001;121:1080–1087
  10. Lewis JD , Aberra FN , Lichtenstein GR , Bilker WB , Brensinger C , Strom BL . Seasonal variation in flares of inflammatory bowel disease . Gastroenterology . 2004;126:665–673
  11. Aberra FN , Brensinger CM , Bilker WB , Lichtenstein GR , Lewis JD . Antibiotic use and the risk of flare of inflammatory bowel diseas . Clin Gastroenterol Hepatol . 2005;3:459–465
  12. Card T , Hubbard R , Logan RF . Mortality in inflammatory bowel disease (a population-based cohort study) . Gastroenterology . 2003;125:1583–1590
  13. Card T , West J , Hubbard R , Logan RF . Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use (a population based cohort study) . Gut . 2004;53:251–255
  14. Van Staa TP , Travis S , Leufkens HG , Logan RF . 5-aminosalicylic acids and the risk of renal disease (a large British epidemiologic study) . Gastroenterology . 2004;126:1733–1739
  15. Marrie RA , Wolfson C , Sturkenboom MC , et al.   Multiple sclerosis and antecedent infections (a case-control study) . Neurology . 2000;54:2307–2310
  16. Hernan MA , Jick SS , Olek MJ , Jick H . Recombinant hepatitis B vaccine and the risk of multiple sclerosis (a prospective study) . Neurology . 2004;63:838–842
  17. Becker KG , Simon RM , Bailey-Wilson JE , et al.   Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases . Proc Natl Acad Sci U S A . 1998;95:9979–9984
  18. Storch I , Sachar D , Katz S . Pulmonary manifestations of inflammatory bowel disease . Inflamm Bowel Dis . 2003;9:104–115
  19. Casey MB , Tazelaar HD , Myers JL , et al.   Noninfectious lung pathology in patients with Crohn’s disease . Am J Surg Pathol . 2003;27:213–219
  20. Ekbom A , Helmick CG , Zack M , Holmberg L , Adami HO . Survival and causes of death in patients with inflammatory bowel disease (a population-based study) . Gastroenterology . 1992;103:954–960
  21. Persson PG , Bernell O , Leijonmarck CE , Farahmand BY , Hellers G , Ahlbom A . Survival and cause-specific mortality in inflammatory bowel disease (a population-based cohort study) . Gastroenterology . 1996;110:1339–1345
  22. Winther KV , Jess T , Langholz E , Munkholm P , Binder V . Survival and cause-specific mortality in ulcerative colitis (follow-up of a population-based cohort in Copenhagen County) . Gastroenterology . 2003;125:1576–1582
  23. Rang EH , Brooke BN , Hermon-Taylor J . Association of ulcerative colitis with multiple sclerosis . Lancet . 1982;2:4
  24. Kimura K , Hunter SF , Thollander MS , et al.   Concurrence of inflammatory bowel disease and multiple sclerosis . Mayo Clin Proc . 2000;75:802–806
  25. Edwards LJ , Constantinescu CS . A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic . Multiple Sclerosis . 2004;10:575–581
  26. Geissler A , Andus T , Roth M . Focal white-matter lesions in brain of patients with inflammatory bowel disease . Lancet . 1995;345:897–898
  27. Gondim FA , Brannagan TH , Sander HW , Chin RL , Latov N . Peripheral neuropathy in patients with inflammatory bowel disease . Brain . 2005;128:867–879
  28. Mohan N , Edwards ET , Cupps TR , et al.   Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides . Arthritis Rheum . 2001;44:2862–2869
  29. Foroozan R , Buono LM , Sergott RC , Savino PJ . Retrobulbar optic neuritis associated with infliximab . Arch Ophthalmol . 2002;120:985–987
  30. Nanavati SA , Ergun GA , Schwartz JT . Avoiding infliximab in the treatment of Crohn’s disease in patients with multiple sclerosis . Am J Gastroenterol . 2003;98:2333–2334
  31. ten Tusscher MP , Jacobs PJ , Busch MJ , de Graaf L , Diemont WL . Bilateral anterior toxic optic neuropathy and the use of infliximab . (letter) BMJ . 2003;326:579
  32. Mejico LJ . Infliximab-associated retrobulbar optic neuritis . Arch Ophthalmol . 2004;122:793–794
  33. Strong BY , Erny BC , Herzenberg H , Razzeca KJ . Retrobulbar optic neuritis associated with infliximab in a patient with Crohn disease . (letter) Ann Intern Med . 2004;140:W34
  34. Thomas CW , Weinshenker BG , Sandborn WJ . Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn’s disease . Inflamm Bowel Dis . 2004;10:28–31
  35. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group . TNF neutralization in MS (results of a randomized, placebo-controlled multicenter study) . Neurology . 1999;53:457–465
  36. Kleinschmidt-DeMasters BK , Tyler KL . Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis . N Engl J Med . 2005;353:369–374
  37. Langer-Gould A , Atlas SW , Green AJ , Bollen AW , Pelletier D . Progressive multifocal leukoencephalopathy in a patient treated with natalizumab . N Engl J Med . 2005;353:375–381
  38. Van Assche G , Van Ranst M , Sciot R , et al.   Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease . N Engl J Med . 2005;353:362–368

 Dr Loftus has received research support from Procter & Gamble Pharmaceuticals, and has served as a consultant for UCB Pharma, Abbott Laboratories, and Prometheus Laboratories.

PII: S0016-5085(05)01550-7

doi: 10.1053/j.gastro.2005.07.042

Gastroenterology
Volume 129, Issue 3 , Pages 1117-1120 , September 2005

Article Tools